ClinicalTrials.gg
RecruitingNCT05397951Updated Apr 17, 2026

The Validation Study of Bioelectronics

An interventional study of Multi-modality Noninvasive Biosensor and Oximeter in Healthy and Health Behavior, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Health Behavior by University of North Carolina, Chapel Hill — 3 open to participants now, 3 under way, none of them phase 3. Health Behavior · University of North Carolina, Chapel Hill.

Planned enrollment
10th of 10
22 · median 384
Started
2024
with 1 other
No phase
10 of 10
3 open now
Registered
5th of 10
by date

Among the 10 studies in Health Behavior by University of North Carolina, Chapel Hill, this one is the 10th largest by planned enrollment, is one of 2 that started in 2024, is one of 10 with no phase, and was the 5th registered.

Health Behavior

970 studies on the registry are indexed under Health Behavior; 166 are open to participants now.

Browse Health Behavior studies →

Open to participants now

3 of the 10 studies in Health Behavior by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 94 Health Behavior studies recruiting now, 39 (41%) set no upper age limit and 38 (40%) stop at 75 or younger; 25 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Health Behavior by University of North Carolina, Chapel Hill, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safe wearability and basic functions of the multi-modality sensors fabricated in the PI lab.

Read the detailed description

Members of this research team have developed innovative, wearable devices capable of being comfortably and continuously worn while recording diverse physiologic measurements. The purpose of this study is to validate the safe wearability and basic functions of the novel biocompatible electronic sensor that will allow continuous, non-invasive physiological measurements. This study aims to obtain preliminary data on the safety and functional aspects of the developed devices and compare it to approved medical equipments (including Abbott Medquip Oximeter, Omron blood pressure monitor, and Vicorder device for pulse wave velocity), which will pave the way for future study that focuses certain disease model. Participants will be randomly assigned to Condition A, and wear the devices before and after exercise for 15 minutes each time, or Condition B and wear the devices for 2 hours continuously. During their 1-hour or 2.5-hour lab visit, study participants will wear the biocompatible electronic sensors and three approved medical devices during a slow deep breath, before and after a 6-minute brisk walk, or for an extended period of time (2 hours). Participants will return to the lab for two brief visits, 48 and 96 hours after the device wearing, to determine if any suspected adverse events related to study procedures or devices emerged after they left the research site. For the future study, we will plan to 1) optimize the devices for use in patients needing FiO2 weaning, 2) demonstrate the reliability, and accuracy of these devices for continuous physiological measurements, including but not limited to blood pressure, heart rate (HR), cerebral blood flow, temperature, glucose concentration, and respiratory rate, and 3) demonstrate these devices are preferred by patients to current measurement tools. Once validated, such sensors could fundamentally change the way blood flow, blood pressure, or related parameters are monitored for patients, eliminating risks associated with invasive monitoring, allowing continuous, real-time detection of clinically meaningful changes in the patients, advancing knowledge of hormonal signatures and physiological signals preceding clinically meaningful events.

03

Conditions studied

  • Healthy
  • Health Behavior

Browse trials for

Keywords

  • sensor
  • non-invasive
  • multi-modality
  • vital signs
  • safe wearability
  • optoelectronic system
  • optical polarimetry
  • near-infrared spectroscopy
  • skin-interfaced
  • wearable
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with ages between 18 and 99.
  • Healthy individuals (not known to suffer any significant illness relevant to the proposed study).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating.
  • History of active () skin disorders that make skin vulnerable to contact conventional electronic devices.
  • History of allergic response to silicones or adhesives (such as 3M Tegaderm).
  • Broken, damaged or irritated skin or rashes near the sensor application sites (finger, wrist, temple, subclavian, arm, neck, and thigh).
  • Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator to ensure safe completion of study tasks.
  • Subjects who are unable to participate in moderate exercise for 6 minutes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Wearing Biosensor Before & After Exercise

    Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices for 15 minutes before and after a brisk 6-minute walk.

    Device: Multi-modality Noninvasive Biosensor · Device: Oximeter · Device: Portable Blood Pressure Monitor · Device: Vicorder Pulse Wave Velocity Monitor

  • Experimental
    Wearing Biosensor for an Extended Period

    Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices continuously for 2 hours.

    Device: Multi-modality Noninvasive Biosensor · Device: Oximeter · Device: Portable Blood Pressure Monitor · Device: Vicorder Pulse Wave Velocity Monitor

Interventions

  • DeviceMulti-modality Noninvasive Biosensor

    The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.

  • DeviceOximeter

    The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.

    Also known as: Abbott Medquip

  • DevicePortable Blood Pressure Monitor

    The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.

    Also known as: Omron

  • DeviceVicorder Pulse Wave Velocity Monitor

    The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.

06

What researchers measure

Primary outcomes

  1. Mean Comfort Level of Wearable Sensors

    A questionnaire about the comfort of the wearable sensors will be measured using the Likert scale, which ranges from 1 to 5 and is used to measure attitudes and perception changes about the our sensor. The minimum value 1 represents "strongly disagree" and the maximum value 5 represents "strongly agree", thus higher scores represent a better outcome.

    Time frame: Questionnaire completed within 96 hours after device application.

  2. Mean Safety Level of Wearable Sensors

    A questionnaire about the safety and reactions to the wearable sensors will be measured using the Likert scale, which ranges from 1 to 5 and is used to measure attitudes and perception changes about the safety of our sensor. The minimum value 1 represents "strongly disagree" and the maximum value 5 represents "strongly agree", thus higher scores represent a better outcome.

    Time frame: Questionnaire completed within 96 hours after device application.

  3. Mean Agreement Over Time of Physiological Parameters between Newly-Fabricated Wearable Sensors and Approved Devices

    Signals from the approved medical devices will measure tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements and these data will be compared to the signals from our sensors. The difference over time will be measured on a scale from a minimum of 0 and a maximum of 1, with 0 being the best outcome and representing the lowest difference between the sensing data from the different devices.

    Time frame: Through study completion, an average of 15 minutes.

07

Study locations

1 of 1 sites recruiting
  • Kenan Laboratories at the University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Hannah L Weisbecker, BS · Contacthannahlw@alumni.unc.edu · 678-641-7484
    • Wubin Bai, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results may be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 9 and continuing for 36 months following publication.

Access criteria: Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with the University of North Carolina at Chapel Hill.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.

Of 569 non-industry interventional studies with no phase under Health Behavior, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's planned 34 months is above that.

Counting every sponsor, half of 587 studies reached it within 15 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 31, 2022
StartActual
Jan 9, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05397951
Collaborators
North Carolina Translational and Clinical Sciences Institute
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Jan 9, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Hannah L Weisbecker, BS
Contact
hannahlw@alumni.unc.edu
6786417484
Wubin Bai, PhD
Contact
wbai@unc.edu
9198439334
Wubin Bai, PhD
principal investigator · Assistant Professor of Applied Physical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion